Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Phase II Study of weekly ABI-007 plus gemcitabine or simplified LV5FU2 as first-line therapy in metastatic pancreatic cancer
2013-001463-23Phase 2Completed
- Sponsor
- GERCOR
- Start
- Sep 2013
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised trial of nab-paclitaxel in pancreatic cancer (PDAC) (2 arms), sponsored by GERCOR. Primary endpoint: Progression-free survival. Started Sep 2013; status: completed.
02
Drugs
nab-paclitaxel
03
Conditions
pancreatic cancer (PDAC)
Beyond the preview
Go deeper on 2013-001463-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001463-23.